154 related articles for article (PubMed ID: 10561325)
1. KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.
Clarke K; Basser RL; Underhill C; Mitchell P; Bartlett J; Cher L; Findlay M; Dalley D; Pell M; Byrne M; Geldard H; Hill JS; Maher D; Fox RM; Green MD; Kaye AH
J Clin Oncol; 1999 Aug; 17(8):2579-84. PubMed ID: 10561325
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients.
Kuratsu JI; Arita N; Kayama T; Kubo N; Mori T; Sawamura Y; Ushio Y
J Neurooncol; 2000 Jun; 48(2):145-9. PubMed ID: 11083079
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of KRN8602(MX2), a novel morpholino anthracycline derivative, in patients with recurrent malignant glioma.
Kuratsu J; Arita N; Kurisu K; Uozumi T; Hayakawa T; Ushio Y
J Neurooncol; 1999 Apr; 42(2):177-81. PubMed ID: 10421076
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer.
Clarke K; Basser RL; Maher D; Morgan DJ; Cebon J; Fox RM; Hill JS; Alt C; Bartlett J; Geldard H; Kaye AH; Green MD
J Clin Oncol; 1998 Jun; 16(6):2181-7. PubMed ID: 9626219
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of KRN8602, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin hydrochloride, MX2 x HCl in patients with metastatic breast cancer.
Katsumata N; Watanabe T; Tominaga T; Ogawa M; Adachi I; Enomoto K; Kajiwara T; Kusama M; Yamada Y; Abe O
Cancer Chemother Pharmacol; 1999; 43(6):441-4. PubMed ID: 10321502
[TBL] [Abstract][Full Text] [Related]
6. MX2; 3'-deamino-3'-morpholino-13-deoxy-10-hydroxycarminomycin (KRN8602) in refractory metastatic breast cancer: results of a preliminary phase II trial.
Watanabe T; Narabayashi M; Haga S; Yamada Y; Kawamura E; Enomoto K; Kusama M; Kimura K; Adachi I; Abe O
Jpn J Clin Oncol; 1993 Aug; 23(4):246-9. PubMed ID: 8411738
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of KRN8602 (MX2) for malignant lymphoma].
Okabe K; Sampi K; Kuraishi Y; Takemoto Y; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1001-6. PubMed ID: 9644314
[TBL] [Abstract][Full Text] [Related]
8. Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Wei-Tsao DD; Blumenthal DT; Glantz MJ
Cancer; 2008 May; 112(9):2038-45. PubMed ID: 18361434
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
Chamberlain MC; Tsao-Wei DD
Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
11. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy using carboplatin (JM-8) and etoposide (JET therapy) for recurrent malignant gliomas: a phase II study.
Watanabe K; Kanaya H; Fujiyama Y; Kim P
Acta Neurochir (Wien); 2002 Dec; 144(12):1265-70; discussion 1270. PubMed ID: 12478337
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Galanis E; Buckner JC; Burch PA; Schaefer PL; Dinapoli RP; Novotny PJ; Scheithauer BW; Rowland KM; Vukov AM; Mailliard JA; Morton RF
J Clin Oncol; 1998 Sep; 16(9):2953-8. PubMed ID: 9738563
[TBL] [Abstract][Full Text] [Related]
14. A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
Pipas JM; Meyer LP; Rhodes CH; Cromwell LD; McDonnell CE; Kingman LS; Rigas JR; Fadul CE
J Neurooncol; 2005 Feb; 71(3):301-5. PubMed ID: 15735921
[TBL] [Abstract][Full Text] [Related]
15. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
16. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
[TBL] [Abstract][Full Text] [Related]
19. Procarbazine and high-dose tamoxifen as a second-line regimen in recurrent high-grade gliomas: a phase II study.
Brandes AA; Ermani M; Turazzi S; Scelzi E; Berti F; Amistà P; Rotilio A; Licata C; Fiorentino MV
J Clin Oncol; 1999 Feb; 17(2):645-50. PubMed ID: 10080610
[TBL] [Abstract][Full Text] [Related]
20. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
